RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+17.63%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$1.7B
AUM Growth
+$1.7B
(+2.6%)
Cap. Flow
-$115M
Cap. Flow
% of AUM
-6.77%
Top 10 Holdings %
Top 10 Hldgs %
43.98%
Holding
67
New
4
Increased
4
Reduced
33
Closed
4
Top Buys
| 1 |
BioNTech
BNTX
|
$18.3M |
| 2 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$10.1M |
| 3 |
Astria Therapeutics
ATXS
|
$3.42M |
| 4 |
Regenxbio
RGNX
|
$3.39M |
| 5 |
Penumbra
PEN
|
$2.69M |
Top Sells
| 1 |
Krystal Biotech
KRYS
|
$38.4M |
| 2 |
Amicus Therapeutics
FOLD
|
$25.1M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$10.2M |
| 4 |
Kymera Therapeutics
KYMR
|
$8.8M |
| 5 |
Replimune Group
REPL
|
$8.56M |
Sector Composition
| 1 | Healthcare | 97.73% |
| 2 | Industrials | 2.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Absci
ABSI
$351M
| $31.5M | 1.86% |
8,253,316
| – | – |
|
27
Boston Scientific
BSX
$158B
| $27.7M | 1.63% |
330,873
-59,380
| -15% | -$4.98M |
|
28
Celldex Therapeutics
CLDX
$1.55B
| $22.3M | 1.32% |
657,175
-61,548
| -9% | -$2.09M |
|
29
IDEAYA Biosciences
IDYA
$2.25B
| $21.6M | 1.27% |
681,150
-78,366
| -10% | -$2.48M |
|
30
Shattuck Labs
STTK
$61.8M
| $19.6M | 1.15% |
5,615,489
| – | – |
|
|
31
BioNTech
BNTX
$24.1B
| $18.3M | 1.08% |
+154,456
| New | +$18.3M |
|
32
Immunovant
IMVT
$2.89B
| $18.3M | 1.08% |
642,229
-77,948
| -11% | -$2.22M |
|
33
4D Molecular Therapeutics
FDMT
$293M
| $13.6M | 0.8% |
1,262,090
+188,655
| +18% | +$2.04M |
|
34
Intuitive Surgical
ISRG
$156B
| $13.1M | 0.77% |
26,698
-13,145
| -33% | -$6.46M |
|
35
Stryker
SYK
$147B
| $11.8M | 0.7% |
32,741
-6,742
| -17% | -$2.44M |
|
36
89bio
ETNB
$1.36B
| $11.6M | 0.68% |
1,569,850
-175,806
| -10% | -$1.3M |
|
37
Ardelyx
ARDX
$1.56B
| $11.4M | 0.67% |
1,660,763
-220,738
| -12% | -$1.52M |
|
38
Establishment Labs
ESTA
$1.11B
| $11.3M | 0.67% |
261,803
+48,779
| +23% | +$2.11M |
|
|
ORKA
39
Oruka Therapeutics, Inc. Common Stock
ORKA
$580M
| $10.1M | 0.59% |
+411,728
| New | +$10.1M |
|
40
Prime Medicine
PRME
$588M
| $8.03M | 0.47% |
2,074,350
| – | – |
|
41
ALX Oncology
ALXO
$54.1M
| $6.98M | 0.41% |
3,836,576
-199,875
| -5% | -$364K |
|
42
Nuvation Bio
NUVB
$1.04B
| $6.94M | 0.41% |
3,031,009
| – | – |
|
|
VERV
43
DELISTED
Verve Therapeutics
VERV
| $6.7M | 0.39% |
1,383,366
-80,040
| -5% | -$387K |
|
44
Repare Therapeutics
RPTX
$73.5M
| $6.68M | 0.39% |
1,942,555
| – | – |
|
45
AC Immune
ACIU
$230M
| $6.4M | 0.38% |
1,694,167
-113,537
| -6% | -$429K |
|
46
Cytokinetics
CYTK
$5.88B
| $5.13M | 0.3% |
97,116
-14,751
| -13% | -$779K |
|
47
Ventyx Biosciences
VTYX
$185M
| $4.59M | 0.27% |
2,107,215
-56,911
| -3% | -$124K |
|
48
Stereotaxis
STXS
$244M
| $4.3M | 0.25% |
2,108,219
| – | – |
|
49
Atara Biotherapeutics
ATRA
$87.6M
| $3.68M | 0.22% |
452,270
| – | – |
|
|
BOLD
50
Boundless Bio
BOLD
$25.3M
| $3.55M | 0.21% |
1,023,548
-11,035
| -1% | -$38.3K |
|